What is Noogutyl?
The catalog uses the spelling Noogutyl. The closely named literature compound is Nooglutyl/Nooglutil, but the listing does not provide enough structural or salt-form information to verify that they are identical.
Mechanism & research focus
Nooglutyl papers describe glutamatergic and AMPA-associated pharmacology. This is literature context for a possible identity match, not a confirmed mechanism for the catalog material.
What the research covers
Primary Nooglutyl studies include rat hemorrhagic-stroke and ischemia models, with neurological and memory-task measurements. A separate human trial studied the named formulation Ampasse; that product's results cannot be assigned to an unspecified Noogutyl capsule.
What remains uncertain
Confirmation requires the exact chemical structure, salt form and analytical identity. Similar spelling and broadly similar marketing categories are insufficient. Neither animal brain-injury findings nor a different clinical formulation establishes cognitive benefit or safety for this listing.
The evidence label describes the linked research, not the suitability of a catalog product for use in people. Formulation, identity, purity, and measured content must be assessed separately.
Sources & studies
Nooglutil in a rat intracerebral hematoma model ↗
Studies Nooglutyl/Nooglutil, not a product explicitly identified as Noogutyl.
Ampasse in chronic cerebrovascular disorders: randomized placebo-controlled trial ↗
124 participants; included to distinguish clinical formulation evidence from an unverified catalog identity.
Read the full paper for its design, controls and limitations. A source link is not a claim that its tested material matches a DA formulation.
Catalog formats & documentation
Formats grouped by compound identity. Availability and batch documentation remain on Disguised Alpha.
Original DA reference: Noogutyl research guide ↗